Welcome to our dedicated page for Zura Bio SEC filings (Ticker: ZURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zura Bio Limited filings document the regulatory record of a Cayman Islands clinical-stage biotechnology company developing antibody candidates for autoimmune and inflammatory diseases. Its disclosures include operating and financial results, Regulation FD materials, clinical-program communications, and risk-related context for a multi-asset immunology pipeline led by tibulizumab (ZB-106).
The company’s SEC record also covers proxy governance matters, annual general meeting voting, executive and compensation arrangements, and capital-structure activity involving Class A ordinary shares, pre-funded warrants, underwriting agreements, and related legal opinions. Current reports and proxy materials provide formal disclosure of material events, shareholder matters, and emerging growth company status.
Zura Bio Limited reported a leadership change in its finance function. On April 20, 2026, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer Eric Hyllengren was separated from the company, with the company stating the separation was not related to its financial or operating results or to any disagreements over operations or reporting practices. Under a Separation Agreement signed April 21, 2026, he will receive severance equal to three months of base salary and reimbursement of COBRA premiums for up to six months, contingent on his compliance with the agreement.
The board appointed Marlyn Mathew, the company’s Vice President, Finance and Accounting, as principal accounting officer and principal financial officer effective April 20, 2026. Her annual base salary was increased to $366,415. Mathew has led finance and accounting at Zura Bio since June 2022 and previously held controller roles at Immunovant. The company notes she has no related‑party arrangements or family relationships with directors or executive officers.
Zura Bio Ltd reported that Chief Technology Officer Gary Whale received an employee share option grant covering 263,000 Class A Ordinary Shares. The options have an exercise price of $6.03 per share and expire on April 1, 2036.
These options were granted as a compensation award rather than an open-market purchase. One fourth of the shares will vest on April 1, 2027, with the remaining options vesting in equal quarterly installments over time, subject to his continuous service.
Zura Bio Ltd reported that officer Kiran Nistala received an option grant for 340,900 Employee Share Options to buy Class A Ordinary Shares at an exercise price of $6.03 per share. These options expire on April 1, 2036 and represent compensation rather than a market purchase.
According to the vesting terms, one fourth of the options will vest on April 1, 2027, with one twelfth of the remaining options vesting in equal quarterly installments thereafter, as long as Nistala continues in service. After this grant, Nistala holds 340,900 derivative securities directly related to this award.
Zura Bio Ltd Chief Financial Officer Eric J. Hyllengren received an employee stock option grant covering 340,900 Class A Ordinary Shares. The option has an exercise price of $6.03 per share and expires on April 1, 2036. This is a compensation-related award, not an open‑market purchase.
According to the vesting schedule, one fourth of the option vests on April 1, 2027, with the remaining three fourths vesting in equal quarterly installments thereafter, subject to his continuous service. Following this grant, he holds options for 340,900 shares directly.
Zura Bio Ltd reported that its Chief Legal Officer, Davis Kim, received an employee stock option grant covering 425,700 Class A Ordinary Shares. The options have an exercise price of $6.03 per share and expire on April 1, 2036.
According to the vesting terms, one fourth of the option award vests on April 1, 2027, with the remaining options vesting in equal quarterly installments thereafter, contingent on Kim’s continued service. This is a compensation-related award rather than an open-market share purchase or sale.
Zura Bio Ltd reported that Chief Executive Officer Sandeep Chidambar Kulkarni received an award of employee share options covering 894,000 Class A Ordinary Shares. The options have an exercise price of 6.03 per share and expire on April 1, 2036.
According to the vesting terms, one fourth of the options will vest on April 1, 2027, and the remaining three fourths will vest in equal quarterly installments thereafter, contingent on his continuous service. Following this grant, he holds 894,000 options directly.
Zura Bio Limited is a clinical-stage biotechnology company focused on autoimmune and inflammatory diseases. It highlights three in-licensed antibody programs: tibulizumab (ZB-106), crebankitug (ZB-168) and torudokimab (ZB-880), all sourced from large pharma partners.
Tibulizumab, a bispecific antibody targeting IL-17A and BAFF, is in two global Phase 2 trials: TibuSHIELD in hidradenitis suppurativa, with topline 16-week data planned for the fourth quarter of 2026, and TibuSURE in diffuse cutaneous systemic sclerosis, with topline 24-week data expected in the first half of 2027.
The filing describes earlier Phase 1 safety and pharmacodynamic data for all three assets, fully outsourced cGMP manufacturing, and composition-of-matter patents generally extending into 2031–2037. It also details substantial milestone and royalty obligations under licenses with Lilly and Pfizer, a Lonza gene-expression license, WuXi Biologics agreements, and a 2025 Athanor letter agreement that included issuing 8,657,402 shares plus cash and future sales-based obligations.
Zura Bio Limited reported full-year 2025 results and highlighted progress across its clinical pipeline and financing. The company posted a net loss of $68.7 million for 2025, compared with $52.4 million in 2024, as research and development spending increased to $42.1 million to advance Phase 2 tibulizumab trials.
Cash and cash equivalents were $109.4 million as of December 31, 2025, down from $176.5 million a year earlier. In February 2026, Zura completed an underwritten equity offering with gross proceeds of about $144 million, and now believes its cash can fund operations through at least the end of 2028.
The Phase 2 TibuSHIELD study in hidradenitis suppurativa expanded planned enrollment to 225 participants, with topline data expected in the fourth quarter of 2026. The TibuSURE Phase 2 study in systemic sclerosis is ongoing, with topline data anticipated in the first half of 2027. Leadership updates include appointing Sandeep Kulkarni, M.D., as Chief Executive Officer in January 2026 and adding two new board members in February 2026.
Zura Bio Limited furnished a new corporate presentation for investors and conferences dated March 10, 2026. The materials are provided under a Regulation FD disclosure to share updated information with the market.
The presentation is available as Exhibit 99.1 and can also be accessed through the company’s investor relations website in the “News & Events” section. The materials are furnished, not filed, and are not automatically incorporated into other SEC filings.
Nirula Ajay reported acquisition or exercise transactions in this Form 4 filing.
Zura Bio Ltd director Ajay Nirula reported receiving a grant of 37,812 share options. These options were awarded on February 21, 2026 and vest in twelve substantially equal monthly installments over one year starting from that date. Any remaining unvested options will vest on the day immediately before the next annual meeting of shareholders following the grant date, as long as he continues in service through each vesting date.